NEW YORK (GenomeWeb News) – Qiagen said after the close of the market Thursday that it has inked a cardiac point-of-care diagnostics alliance in China with Lepu Medical Technology, a medical device firm based in Beijing.

Under the deal, Lepu will market in China Qiagen's ESEQuant Lateral Flow System with five cardiac marker tests developed by Lepu intended to diagnose acute myocardial infarction. According to Qiagen, the system will be used in emergency rooms and the tests will be able to provide an accurate diagnosis within minutes at the point of care

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.